Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-myeloablative Stem Cell Transplant for Sickle Cell Disease and Beta-Thalassemia
NCT07599176Phase 2Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2026
- Primary completion
- Jun 2032
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept, alemtuzumab in sickle cell disease (SCD), beta thalassemia, sponsored by National Heart, Lung, and Blood Institute. Started Jul 2026; status: recruiting.
02
Drugs
abataceptalemtuzumab
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT07599176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599176.